Location: China
Total raised: $150M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.04.2026 | Series B | $150M | Sinovation... |
Mentions in press and media 12
| Date | Title | Description |
| 04.04.2026 | Syneron Bio Fuels Innovation with $150M Investment | Syneron Bio secured $150 million in Series B financing. This major investment drives its intelligent Synova platform. The capital fuels advanced macrocyclic peptide drug discovery. It targets critical unmet needs across oncology, autoimmune... |
| 03.04.2026 | Months after $100M series A, Syneron closes $150M round to support peptide platform | After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug discovery company Syneron Bio has announced the closing of a $150 million series B round to support its macrocyclic ... |
| 03.04.2026 | Syneron Bio Announces Completion of $150 Million Series B Financing | BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international ... |
| 03.04.2026 | Syneron Bio Raises $150M for Peptide Drug Platform | Syneron Bio, the first company ever to develop systems for rational discovery of intelligent macrocyclic peptides, announced today that it has successfully closed a Series B round of financing totalling $150 million. This significant invest... |
| 03.04.2026 | Syneron Bio: $150 Million Raised For Macrocyclic Peptide Drug Discovery Platform And Pipeline Advancement | Syneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development... |
| 03.04.2026 | Syneron Bio Closes $150M Series B Financing | Syneron Bio, a Beijing, China-based intelligent platform-driven macrocyclic peptide drug discovery company, closed a $150m Series B financing round. The round was led by an international life-science fund, with co-lead participation from De... |
| 21.12.2025 | Syneron Bio Raises Nearly $100M in Series A and A+ Funding Rounds | Syneron Bio, a Beijing, China-based developer of an intelligent high-throughput macrocyclic peptide drug discovery platform, raised nearly $100m in Series A and A+ funding rounds. Backers included AstraZeneca, Pfizer Biotech Development Inv... |
| 11.12.2025 | AstraZeneca, its China joint fund lead nearly $100m financing in Syneron Bio | - |
| 21.03.2025 | AstraZeneca's Bold Leap into Beijing: A New Era for Biopharmaceutical Innovation | AstraZeneca is making waves in the biopharmaceutical ocean. The company recently announced a staggering $2.5 billion investment in Beijing. This move is not just a financial commitment; it’s a strategic pivot that could reshape the landscap... |
| 21.03.2025 | AZN invests $2.5bn in Beijing R&D & manufacturing | AZN invests $2.5bn in Beijing R&D & manufacturing Fri, Mar 21, 2025 12:37 CET Report this content 21 March 2025 AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beiji... |
Show more